Beyond Air, Inc. (NASDAQ:XAIR) Short Interest Down 24.4% in December

Beyond Air, Inc. (NASDAQ:XAIR) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 1,180,000 shares, a decrease of 24.4% from the November 30th total of 1,560,000 shares. Based on an average trading volume of 751,200 shares, the short-interest ratio is presently 1.6 days.

Beyond Air Price Performance

Shares of NASDAQ XAIR opened at $0.44 on Monday. The company has a current ratio of 5.76, a quick ratio of 5.38 and a debt-to-equity ratio of 0.37. The stock has a fifty day simple moving average of $0.48 and a two-hundred day simple moving average of $0.52. Beyond Air has a 1-year low of $0.30 and a 1-year high of $2.20. The firm has a market cap of $31.76 million, a price-to-earnings ratio of -0.31 and a beta of -0.23.

Beyond Air (NASDAQ:XAIR) last posted its quarterly earnings results on Monday, November 11th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.02. Beyond Air had a negative return on equity of 227.29% and a negative net margin of 2,369.17%. The company had revenue of $0.80 million during the quarter, compared to the consensus estimate of $1.19 million. During the same quarter in the prior year, the company earned ($0.51) EPS. Analysts anticipate that Beyond Air will post -0.78 earnings per share for the current year.

Institutional Trading of Beyond Air

A hedge fund recently bought a new stake in Beyond Air stock. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Beyond Air, Inc. (NASDAQ:XAIR) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 87,568 shares of the company’s stock, valued at approximately $47,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.19% of Beyond Air at the end of the most recent reporting period. Hedge funds and other institutional investors own 31.50% of the company’s stock.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.